

Cell Therapy CDMO Services Cell Therapies. Delivered.



Flyer

Minaris Cell Therapies is a dedicated cell therapy CDMO partner helping innovators advance autologous and allogeneic therapies from process development through GMP manufacturing, testing, release, and commercialization.

25+

Years of cell therapy experience

4

Commercially experienced sites across 3 continents

With deep technical expertise, proven quality systems, and commercially experienced sites across three continents, we help bring complex therapies closer to the patients waiting for them.

7,500+

Clinical and commercial GMP batches produced

30+

Inspections passed by global health authorities

The Patient is Waiting

Integrated capabilities designed to accelerate patient delivery

Fully Integrated Development, Manufacturing & Testing

Gain greater control over timelines and costs with one partner supporting the full product lifecycle — from development through release testing.



Strategically Located Global Footprint

Enable broader patient reach through sites positioned in major transportation hubs across North America, Europe, and Asia.



Digital Tracking & Real-Time Updates

Improve transparency, reliability, and execution with digital systems designed to support visibility across complex cell therapy programs.

Cell Therapy Experience

25+ years of manufacturing experience spanning from clinical supply to global commercial product launches for multiple modalities, including:

| **Autologous and allogeneic cell therapies**
— gene-modified and non-gene-modified

| **Multiple immune cell types** — T cells, NK cells, B cells, TILs, dendritic cells, and Tregs

| **Stem cell therapies**
— HPC, HSC, MSC, and iPSC-based products

| **Cell banking** — master and working cell banks with integrated release testing

Cell Therapy Capabilities

One integrated partner. Fewer handoffs. Greater control from development to release.

Design & Optimize

Process and analytical development to support scalable, phase-appropriate manufacturing

Workflow optimization and automation to improve consistency, efficiency, and control

Program-specific strategy for reagents, equipment, assays, and tech transfer

Manufacture

Clinical-to-commercial GMP infrastructure to support programs from early stage through launch

Closed-system, scalable platforms tailored to modality-specific requirements

Commercial-ready execution supported by mature quality systems and flexible capacity

Test & Release

In-house QC release testing to support faster, more controlled batch release

Safety, potency, and characterization assays aligned to product and regulatory requirements

Integrated testing services to reduce handoffs and improve timeline visibility

Commitment to Quality

CMC, Regulatory Support, & Quality Management

Our sites operate under a globally harmonized quality system with integrated testing services to streamline release and enable scale.



FDA



EMA



PMDA

Proven Track Record Across Global GMP Operations



30+ inspections passed from global health authorities, including FDA, EMA, TGA, PMDA, MFDS, and USDA



100+ client and QP-led audits annually, with on-site and virtual audit capabilities



Commercial manufacturing experience with multiple products manufactured globally



Integrated manufacturing, testing, and release workflows to reducing handoffs and supporting streamlined execution from development through GMP supply

Connect with us to accelerate your cell therapy program

Whether you are preparing for first-in-human studies, advancing through clinical development, or scaling for commercial supply, Minaris Cell Therapies brings the experience, quality systems, and integrated capabilities to help move your program forward.

[Contact Minaris Cell Therapies](#)



FL-C-261072-3

©2026 Minaris Advanced Therapies, LLC. All Rights Reserved.

CONTACT US

Get in Touch With Our Team Today



minaris.com/contact

